Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

NCT01801358 is registered in ClinicalTrials.gov with Array Biopharma, now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT01801358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01801358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Phase
Phase 1/2
Overall status
Terminated
Start date
August 31, 2013
Completion date
May 31, 2015
Enrollment
38 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma